Problems With Alternative Levothyroxine In France Force Merck To Switch Back To Original
Executive Summary
French patients who have experienced adverse reactions to a new formulation of Merck KGaA’s hypothyroidism drug Levothyrox are to be given temporary access to the original formulation, pending the availability of other brands of levothyroxine. Merck says the vast majority of patients have had no problems with the new version.